... to in the content or advertisements. 2023 T-cell blast crisis Chronic myeloid leukemia Allogeneic bone marrow transplantation The Philadelphia chromosome (t(9; 22) (q34; q11)) is the hallmark of chronic myelogenous leukemia (CML) but is also present in 15–30% of adult B-cell acute lymphoblastic...

...Ali McBride; John Brokars; Sheila Reiss Reddy; Eunice Chang; Marian H. Tarbox; Thomas W. LeBlanc Introduction: Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited. We...

... to treatment. Methods: We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. Results: A relationship between the IRF4 expression and the disease burden was observed...

...Tamar Berger; Adi Shacham Abulafia; Shai Shimony; Oren Pasvolsky; Iuliana Vaxman; Yifat Miron; Shimrit Feldman; Avi Leader; Pia Raanani Introduction: Data regarding the prevalence of paraproteinemia in patients with chronic myeloid leukemia (CML) are lacking. Methods: To evaluate for the prevalence...

...Jolanta Dengler; Hans Tesch; Kathleen Jentsch-Ullrich; Anke Gerhardt; Clemens Schulte; Jörg Lipke; Gunnar Löwe; Alexander Kiani Introduction: Treatment-free remission (TFR) is increasingly considered as treatment goal for patients with chronic myeloid leukemia (CML), but information...

..., instructions or products referred to in the content or advertisements. Chronic myeloid leukemia Hereditary cancer syndromes Familial cancer National Institutes of Health (NIH) 10.13039/100000002 Unlike other myeloid malignancies, CML is a largely homogeneous disease almost...

... Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However...

... Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only...

... (NG-TKIs; including dasatinib, nilotinib, bosutinib, radotinib, and ponatinib) versus imatinib for patients with newly diagnosed chronic myeloid leukemia (CML). Summary: We identified randomized controlled trials comparing the efficacy of NG-TKIs versus imatinib as the first-line treatment for CML...

...; Andrea Biondi; Franco Locatelli; Robin Foà Background: To date, no data on the adherence to specific guidelines for children with chronic myeloid leukemia (CML) in chronic phase (CP) have been reported. Methods: Since 2001, guidelines for treatment with imatinib mesylate (IM) and monitoring in patients...

... stimulated CD3+ cells from 38 chronic myeloid leukemia (CML) patients. At the time of diagnosis the percentages of cells producing INF-γ, TNF-α, and IL-2 were strongly suppressed compared to those in healthy control subjects. Hematological remission achieved through treatment with tyrosine-kinase inhibitors...

...Guili Zhang; Fei Dong; Caifu Luan; Xia Zhang; Huiyuan Shao; Jie Liu; Chengming Sun We aimed to investigate the role of CCAAT enhancer-binding protein α (C/EBPα) in the pathogenesis of chronic myeloid leukemia (CML) and the mechanism underlying its effect. Bone marrow specimens from 50 patients...

.... Received daily dose Medication adherence Prescribed daily dose Chronic myeloid leukemia Imatinib Chronic myeloid leukemia (CML) is a clonal disease of hematopoietic stem cells and is characterized by the presence of the Philadelphia chromosome and its oncogenic product p210 (BCR-ABL1) [ 1...

...Ho-Young Yhim; Na-Ri Lee; Eun-Kee Song; Chang-Yeol Yim; So Yeon Jeon; Bohee Lee; Jeong-A Kim; Hee Sun Kim; Eun Hae Cho; Jae-Yong Kwak Background: Imatinib mesylate (IM) discontinuation is under active investigation in chronic myeloid leukemia-chronic phase (CML-CP) patients with undetectable...

... Lorand-Metze; Katia Borgia Barbosa Pagnano Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib who switched therapy to dasatinib (n = 33) or nilotinib (n = 21...

...Nawal F. Alshehry; Mohammed Al-Huneini; Jeffrey H. Lipton; Fotios V. Michelis Lymphoproliferative disorders presenting simultaneously with or subsequent to the occurrence of chronic myeloid leukemia (CML) have rarely been reported. Herein, we report 8 cases of a variety of lymphoproliferative...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute leukemia (adult) Acute leukemia in childhood BCR-ABL Chronic myeloid leukemia The t(9;22)(q34;q11...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Chronic myeloid leukemia Imatinib The established dose of imatinib...

... (TKIs) on the expression of apoptosis-related genes (BCL-2 and death receptor family members) in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood mononuclear cells from 32 healthy subjects and 26 CML patients were evaluated before and after treatment with imatinib mesylate (IM...

... 2014 29 10 2014 Chronic myeloid leukemia High-performance liquid chromatography and tandem mass spectrometry Human organic cation transporter 1 Imatinib trough level (C min ) Indirect immunofluorescence flow cytometry A total of 83 patients who were diagnosed...